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Abstract (250 words) 
Sheeppox is a transboundary disease of small ruminants caused by infection with the capripoxvirus 
sheeppox virus (SPPV). Sheeppox is found in Africa, the Middle East and Asia and is characterised by 
fever, multifocal cutaneous raised lesions, and death. Vaccination with live attenuated capripoxvirus 
(CPPV) strains is an effective and widely used strategy to contol sheeppox outbreaks, however there 
are few reports of post-vaccination field surveillance studies. This study used a commercially 
available ELISA to examine quantitative and temporal features of the humoral response of sheep 
vaccinated with a live attenuated CPPV strain in Mongolia. 400 samples were tested using the ELISA 
 
 




commercial kit, and a subset of 45 samples were also tested with a virus neutralisation test (VNT). 
There was substantial agreement between the VNT and ELISA tests. Antibodies to CPPV were 
detected between 40 and 262 days post vaccination. There was no significant difference between 
serological status (positive / negative) and sex or age, however an inverse correlation was found 
between the length of time since vaccination and serological status. Animals between 90 and 180 
days post-vaccination were more likely to be positive than animals greater than 180 days post 
vaccination. Our results show that a commercial CPPV ELISA kit is a robust and reliable assay for post 
CPPV vaccination surveillance in resource-restricted settings and provide temporal parameters to be 
considered when planning sheeppox post-vaccination monitoring programmes.  
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Sheeppox (SP), goatpox (GP) and lumpy skin disease (LSD) are transboundary diseases caused by 
infection with viruses of the genus capripoxvirus (CPPV), namely sheeppox virus (SPPV), goatpox 
virus (GTPV) and lumpy skin disease virus (LSDV). All three viruses cause systemic disease in 
ruminants characterised by fever, multifocal cutaneous raised lesions, and death. LSDV causes 
disease only in cattle, while SPPV and GTPV cause disease in sheep and goats. The host preference of 
SPPV and GTPV varies with some isolates of SPPV causing disease only in sheep, some isolates of 
GTPV causing disease only in goats, and some isolates of SPPV and GTPV causing disease in both 
sheep and goats [1]. SP and GP are high consequence diseases. They reduce production of meat, 
 
 




milk, wool and cashmere and decrease the value of affected animals, therefore having a substantial 
negative effect on farmers’ livelihoods [2-5]. Furthermore, countries with endemic SP or GP face 
restrictions on trade of live animals and animal products [6].  
 
Mongolia is a landlocked country located in central Asia bordered by Russia to the north and China 
to the south, east and west. Mongolia has one of the highest livestock per capita ratios in the world, 
with a human population of 3.2 million compared to 4.3 million cattle, 30.1 million sheep and 27.3 
million goats [7]. Since 1977 there have been three SP outbreaks in Mongolia: the 2006-2007 
outbreak affecting five provinces [8], the 2013 outbreak affecting two provinces, and the extensive 
2015-2017 outbreak affecting eight provinces. During this latest, the Mongolian General Authority 
for Veterinary Services (GAVS) started a risk-based vaccination campaign as a control strategy. In 
2016 a targeted post-vaccination surveillance programme was employed. 
 
Vaccination is considered one of the most effective methods for control of CPPVs [6]. Live-
attenuated strains of SPPV and GTPV are the most common type of vaccine used against SP and GP, 
however the duration of the humoral immune response following vaccination with live attenuated 
CPPV vaccines is poorly understood. Manufacturers often recommend annual vaccination regimes to 
maintain herd immunity, however these recommendations are often based on research conducted 
for LSD in cattle and/or under controlled conditions [9-12]. There is very little published research 
describing the humoral immune response following regional or national vaccination programmes to 
protect against SP or GP.  
 
 
In this study we used a subset of serum samples collected from sheep during post-vaccination 
surveillance in Mongolia to investigate the humoral immune response of vaccinated sheep following 
 
 




a risk-based SP vaccination campaign. We used the results to identify potential factors that might 
play a role in the detection of seroconversion and to assess the suitability of a commercial ELISA test 





All animals were vaccinated with a live attenuated capripoxvirus vaccine produced by Biocombinat 
SOI, in Mongolia. The sheeppox vaccine was the live-attenuated SPPV Perego strain (original date 
1978), grown in primary lamb testis cell cultures. The vaccine was administered to sheep 
subcutaneously into a hairless skin area (fore-flank or tail patch) in compliance with Mongolian 
hygiene regulations. Mongolia does not carry out sheeppox vaccination programmes routinely, 




Blood samples from sheep were collected as part of the post-vaccination surveillance programme 
for SP implemented by the Mongolian General Authority for Veterinary Services (GAVS) in 2016. All 
provinces that were part of the vaccination programme in the country (n=8; Figure 1) were part of 
the post-vaccination monitoring evaluation. Multistage sampling was used to select animals for 
testing. Briefly, in each province between one and three soums (or districts) were randomly 
selected. Within each soum herds were randomly selected and 20 sheep in each herd were 
randomly selected for sampling. A total of 2000 samples were collected. 
 
 




For each sample collected, herder location (province and soum name), name of the herder/owner, 
age and sex of the animal, date when the animal was last vaccinated for SP (according to the 
vaccination records) and date of sampling was recorded.   
 
Sample processing 
Blood samples were stored at 4°C to clot after which the separated serum was collected. Samples 
were stored at 4°C and transported to the State Central Veterinary Laboratory (SCVL) of Mongolia, in 
Ulaanbaatar, within two days post-collection. On receipt, serum samples were centrifuged at 3000 
rpm for 10 min, serum supernatant collected, aliquoted, and stored at -20°C.  
 
ELISA 
From the 2000 samples collected as part of the post-vaccination monitoring, 400 samples were 
randomly selected for comparative serological testing by both SCVL in Mongolia and The Pirbright 
Institute in the UK using a commercially available ELISA (ID Screen® Capripox Double Antigen Multi-
species ELISA kit; IDvet, Grabels, France) following manufacturer instructions. Aliquots of the same 
serum samples were tested singly at both the SCVL and Pirbright. The optical density readings were 
used to calculate the percentage of seropositivity (%SP) for each sample. A sample with a %SP value 
of ≥ 30% was considered positive.  
 
Fluorescent Virus Neutralisation Test (FVNT) 
The recombinant EGFP-095-LSDV Neethling virus was generated through insertion of the EGFP 
marker at the N terminus of the LSDV ORF 095, encoding for a putative core protein of the LSDV 
Neethling strain (GenBank: AF409138.1). BS-C-1 (ATCC® CCL-26™) cells were infected with the LSDV 
Neethling strain at a MOI of 0.1. Two hours after infection, cells were transfected with a 
recombinant transfer plasmid carrying the EGFP sequence fused to the LSDV095 gene and flanked by 
 
 




an upstream and a downstream LSDV homology region of, respectively, 427 bp and 338 bp. 
Infected/transfected cells were incubated for about five days during which homologous 
recombination occurred between the LSDV DNA genome and the recombinant construct. After the 
incubation period, single EGFP positive BS-C-1 cells were sorted into pre-seeded 96-well plates twice 
using a BD FACSAria™ III sorter (BD Biosciences). The recombinant fluorescent virus was recovered 
from supernatants of infected cell lysates and separated from the parental virus through 5-fold 
limiting dilutions of the viral suspension. The isolated recombinant EGFP-095-LSDV Neethling virus 
was then purified through a sucrose cushion to obtain a working stock to be used in the 
development of the FVNT. Full genome sequencing of EGFP-095-LSDV Neethling was carried out to 
confirm the genetic modification (data not shown).  
 
Forty-five serum samples were selected and tested for neutralising antibodies by the FVNT. Samples 
were randomly selected based on the ELISA test results spread over time. Time between vaccination 
and sampling was re-categorised into (i) short (<98 days), (ii) medium (99 to 132 days) and (iii) long 
(>133 days), and %SP values were re-categorised into (i) low (%S/P ≤ 0.50), (ii) medium (%SP 0.51 to 
74.38) and (iii) high (%S/P ≥ 74.39), using the first and the third quartile as cut-offs in both cases. 
Samples were then grouped into the nine categories and five samples selected from each category 
for testing by FVNT.  
 
Briefly, Madin-Darby bovine kidney (MDBK) cells were seeded in 96-well tissue culture plates 
(Corning) at a cell suspension of 3 x 105 cells/ml and incubated overnight at 37°C in a 5 % CO2 
incubator. All sample and control sera were heat-inactivated at 56°C for 30 min and diluted 1:10 in 
culture medium (DMEM supplemented with 100 IU/ml penicillin, 100 µg/ml streptomycin and 2.5 % 
heat-inactivated fetal bovine serum; Life Technologies). Twofold serial dilutions (1:10 to 1:1280) 
were then prepared from the test sera. To all serum samples, an equal volume of EGFP-095-LSDV 
 
 




Neethling virus (7 x 102 PFU/ml) was added, and samples incubated at 37°C for 1 h in a 5 % CO2 
incubator. In addition to the serum controls, a cell and virus only control were included. All sample 
and control sera were tested in duplicate.  
To corresponding wells, 150 µl of the test and control serum samples were added to prepared MDBK 
cells and plates incubated at 37°C in a 5 % CO2 incubator for 4 days. Fluorescent foci (indicative of 
cytopathic effect) were determined using a fluorescent UV light microscope (Olympus CKX53). The 
neutralising antibody titre for each sample was determined as the highest dilution at which no foci 
were identified, indicative of complete neutralisation. 
 
Statistical analysis 
Considering FVNT test as the gold standard, diagnostic sensitivity (Dse) and specificity (Dsp) of the 
ELISA was calculated.  
McNemar’s chi-squared test for paired data was used to assess whether there was a statistically 
significant difference in the proportion positive between (i) FVNT and ELISA test results from SCVL in 
Mongolia (n=45), (ii) FVNT and ELISA test results from Pirbright in the UK (n=45) and (iii) ELISA test 
results from SCVL in Mongolia and Pirbright in the UK (n=400). 
Descriptive statistics were obtained for all sheep tested in both laboratories (n=400). Frequency 
distribution of values were explored for time between vaccination and sampling, and %SP values for 
the ELISA test considering the results from each lab separately. For samples in which the exact date 
of vaccination was not available and a range of potential time was given (e.g. May 2016 or between 
15th of May and 15th of June), the midpoint date within this range was considered. The extent to 
which sex, age, time (in days) since vaccination and Province were associated with seroconversion 
(positive / negative) was determined using univariable mixed effects binomial models including 
herder as random effect. Age was re-categorised as ≤1year and >1 year to consider that sheep aged 
more than 1 year might have been vaccinated more than once. Time since vaccination was re-
 
 




categorised in to 3 categories (<90 days, 91 to 180 days and >180 days) based on the expected 
dynamics of the immune response [10, 12, 13]. Collinearity was assessed between all predictor 
variables for which P < 0.2 in the univariate analysis and, when present, only one of the variables 
was kept in the model. Multivariable analysis was used to assess the relationship between the 
individual predictor variables and the outcome, accounting for the potential confounding effect of 
other variables. The %SP values were used to classify animals as positive / negative. The analysis was 
conducted using the results from each laboratory separately. 
Statistical analysis was performed in R.3.3.2 (R Development Core Team 2017) using packages EpiR, 




Blood samples were collected between 23rd and 30th of August 2016 from 400 sheep that had all 
been vaccinated with a live attenuated capripoxvirus vaccine. The 400 samples came from sheep 
herds belonging to 77 herders from seven provinces. Two thirds of the sheep (266; 66.5%) were 
female and 134 (33.5%) were male. Age ranged between 1 and 9 years (median 4 years) with similar 
age distribution between male and females. Time between vaccination and sampling ranged from 40 
to 243 days (median 116 days). Day of vaccination was not recorded in four animals.  
 
The 400 serum samples were tested in both the SCVL (Mongolia) and Pirbright (UK) using the ID 
Screen® Capripox Double Antigen Multi-species ELISA kit (IDvet) following the manufacturer’s 
instructions, and the results from the two laboratories compared. A higher number of samples were 
classified as positive when tested in SCVL (n=188; 47%) compared to Pirbright (n=165; 41.3%), this 








The Virus Neutralisation Test (VNT) is considered the gold standard for assessing the level of 
protective immunity (neutralising antibodies) to CPPV with high specificity [14]. Therefore 45 serum 
samples, representing a sample spread across time post vaccination and ELISA test result, were 
tested for the presence of neutralising antibodies using a fluorescent virus neutralisation test 
(FVNT). Out of the 45 samples selected to be tested by FVNT, 20 were deemed positive. Using the 
ELISA performed in SCVL (Mongolia), 22 of these 45 samples tested positive. Using the ELISA 
performed at Pirbright (UK), 18 tested positive (Tables 2 and 3). The range of values for those 
samples that were deemed positive are presented in Figure 2. There was a substantial agreement 
between the FVNT and ELISA tests regardless of the lab where the samples were tested (Kappa 0.82 














40 41.93 Positive 83 Positive 80 Positive 
40 0 Negative 2.09 Negative 0 Negative 
40 3.01 Negative 0 Negative 0 Negative 
40 5.32 Negative 2.58 Negative 0 Negative 
74 45.7 Positive 0.48 Negative 0 Negative 
75 17.2 Negative 0 Negative 0 Negative 
76 1.61 Negative 0 Negative 0 Negative 
76 9.07 Negative 1.25 Negative 0 Negative 
76 29.23 Negative 0 Negative 0 Negative 
77 232.86 Positive 210.9 Positive 480 Positive 
77 160.18 Positive 32.81 Positive 120 Positive 
80 7.81 Negative 0.55 Negative 0 Negative 
80 117.84 Positive 325.5 Positive 320 Positive 
80 156.96 Positive 49.47 Positive 80 Positive 
81 83.47 Positive 82.25 Positive 120 Positive 
92 26.77 Negative 1.42 Negative 0 Negative 
92 72.25 Positive 143.3 Positive 30 Positive 
92 62.25 Positive 0.32 Negative 0 Negative 
102 1.91 Negative 3.7 Negative 0 Negative 
107 46.07 Positive 0 Negative 0 Negative 
110 105.24 Positive 54.56 Positive 30 Positive 
114 3.63 Negative 0.26 Negative 0 Negative 
114 24.4 Negative 0 Negative 0 Negative 
119 33.47 Positive 0 Negative 10 Positive 
121 14.76 Negative 22.32 Negative 20 Positive 
 
 




122 0.11 Negative 139.5 Positive 60 Positive 
122 34.83 Positive 181.6 Positive 160 Positive 
122 173.3 Positive 400.1 Positive 1280 Positive 
130 88.57 Positive 130.7 Positive 60 Positive 
131 0 Negative 3.76 Negative 0 Negative 
131 0 Negative 0 Negative 0 Negative 
131 158.88 Positive 252.2 Positive 30 Positive 
132 0 Negative 6.6 Negative 0 Negative 
133 50.27 Positive 101.2 Positive 160 Positive 
135 40.82 Positive 46.3 Positive 0 Negative 
135 0 Negative 0 Negative 0 Negative 
193 43.25 Positive 3.49 Negative 20 Positive 
229 132.41 Positive 169.2 Positive 80 Positive 
229 132.19 Positive 185.3 Positive 60 Positive 
229 0 Negative 2.07 Negative 0 Negative 
229 0 Negative 0.03 Negative 0 Negative 
234 0 Negative 0.19 Negative 0 Negative 
234 0 Negative 1.53 Negative 0 Negative 
236 121.73 Positive 255 Positive 640 Positive 
243 0 Negative 0.3 Negative 0 Negative 
 
Table 3). Considering FVNT as the gold standard, the Dse of the ELISA test was slightly better when 
used in Mongolia (0.90; 95% CI 0.66 – 0.98) than when used in the UK (0.85; 95% CI 0.61 – 0.96); 
while the Dsp was better in the UK (0.96; 95% CI 0.78 – 0.99) than in Mongolia (0.84; 95% CI 0.63 – 
0.95). In other words, there were less false positives when the samples were tested in the UK and 
less false negatives when the samples were tested in  Mongolia. 
 
The 188 positive samples from the SCVL dataset are represented in Figure 3. Positive ELISA results 
were detected from day 40 to 243 post-vaccination. The ELISA dataset was used to identify factors 
which might influence seroconversion. An inverse correlation was found between the length of time 
since vaccination and serological status (Figure 3) with a statistically significant difference between 
short (up to 90 days) and long periods of time (>180 days) (Table 4; Supplementary material tables 
S1 and S2). There was no significant difference between serological status (positive / negative) and 
sex or age (Table 4). Differences were found between serological status and province (Table 4), 
 
 




however, length of time since vaccination and province exhibited strong collinearity (Supplementary 
material table S3) and therefore the univariate models were kept. The same patterns were found 
using ELISA results from both labs (Table 4). 
Discussion 
 
This study examined the humoral immune response of sheep to vaccination with a live-attenuated 
capripoxvirus vaccine. Most importantly, the study evaluates sheeppox vaccination under field 
condition, therefore addressing a key gap in literature.  
 
The inter-assay repeatability of the ELISA was examined by testing the same 400 samples using the 
same kit and protocol but in two different laboratories. The results from the two datasets differed 
slightly when compared, with a higher number of samples classified as positive when tested in SCVL 
compared to Pirbright. The differences between the ELISA results reported from the SCVL and 
Pirbright laboratories may be due to differences in equipment, users, environment (such as storage 
conditions of samples) or the quality control regimes in the two laboratories. Unfortunately, the 
limited volume of sera precluded the re-analysis of samples which may have helped resolve the 
differences in results. 
 
The FVNT was used as a gold standard to determine the Dse and Dsp of the ELISA. The two sets of 
ELISA results were in substantive agreement with the FNVT across the 45 sera tested. The values 
calculated using data from SCVL and Pirbright were Dsp 84% and 96%, and Dse 90% and 85%, 
respectively. These are similar to parameters previously reported for ELISA conducted in cattle with 
LSD (Dsp 87% and Dse 91%) [12] but lower than the Dsp data reported by IDvet (Dsp 99.7%) [15]. 
This difference in Dsp estimate may be attributed to the origin of the samples used (field versus 
 
 




experimental), the level of antibodies present in the sample and the sample quality (e.g. haemolysis) 
[13, 16]. 
 
Occasional disagreements between the ELISA and FVNT were not unexpected as they are 
fundamentally different tests that detect different subsets of antibodies. The ELISA detects 
antibodies against immunogenic CPPV antigens, whereas the FVNT detects antibodies with the 
ability to neutralise CPPV. Sporadic disagreement between CPPV serological tests, particularly at 
early times post-infection or post-vaccination, has been reported previously [12, 15]. This should be 
a factor to consider when designing the timing of a CPPV ELISA-based post-vaccination testing 
programme. 
  
ELISAs, IPMA, virus / serum neutralisation tests and immunofluorescent antibody tests have all been 
published for detecting humoral response to CPPV and recently comprehensively reviewed [15]. The 
ELISA is the easiest and cheapest of the four techniques and the most suitable for inter-laboratory 
standardisation. The IDvet ELISA has been validated in a number of peer-reviewed publications, 
showing good concordance with the VNT [12, 13, 17, 18]. Most of these studies use sera from cattle 
vaccinated or infected with LSDV. This study reports the use of the IDvet ELISA with CPPV vaccine 
field sera, demonstrating that it provided a high throughput means of assessing the overall CPPV 
antibody status of a large cohort of animals, therefore broadening the potential utility of the test.  
  
Examination of factors which might influence seroconversion in the sheep identified no significant 
difference between serological status (positive / negative) and sex or age but did find an inverse 
correlation between serological status and the length of time since vaccination. Differences were 
also found between serological status and province, with the data suggesting this is due to timing of 
vaccination in different provinces. There were no important different geographic, environmental, or 
 
 




cultural features or husbandry practices identified between the provinces, which are all in the 
eastern and central region of Mongolia. 
 
A temporal response similar to that reported previously [9, 10, 12, 19] was seen in our study, with a 
correlation found between length of time since vaccination and serological status as measured by 
commercial ELISA. The ELISA detected seroconversion between 40 and 76 days post-vaccination 
albeit with borderline positive %SP values at these time points. Animals categorised into medium 
time period post-vaccination (between 90 and 180 days) were more likely to be positive and animals 
categorised into the group with long time period (>180days) were less likely to be positive. 
Antibodies against CPPV were still detected in this study in four samples at 236 days post 
vaccination. A limitation of this study is that sheep were only tested at one point in time. In the 
future, longitudinal studies with fewer animals tested but at frequent and uniform intervals post 
vaccination, particularly at early timepoints, would be beneficial and should be implemented in 
future post vaccination monitoring programmes.  
 
Correlating antibody levels with protection against viral challenge requires further study. Antibodies 
alone are known to provide protection against poxviral disease including SP [20-22], and levels of 
poxvirus antibodies, measured either by ELISA or neutralisation assay, are often used as a correlate 
of protective immunity in people and animals. However, the level of antibodies that confers 
protection against poxviruses is unknown. One study found people with pre-existing neutralizing 
titres <1:32 against vaccinia virus were more susceptible to smallpox infection than those with 
antibody titers ≥1:32 [23]. A neutralisation index (calculated as the log titre difference between the 
titre of the virus in the negative serum and in the test serum) of ≥1.5 is considered positive for LSDV, 
SPPV and GTPV [14] although there is no data to link this index with protection from challenge. 
Importantly, a low antibody response by ELISA or neutralisation tests post-vaccination may not 
 
 




necessarily mean absence of protection as (i) there may be sufficient memory B cells present to 
provide a rapid anamnestic antibody response and therefore protection post challenge [24], (ii) it is 
likely only a low amount of neutralising antibodies is required for protection [25, 26], and (iii) cell 
mediated immunity or non-neutralising antibodies may provide protection. The levels of antibodies 
detected at later time points in this study (>180 days) were lower than earlier time points. While this 
indicates that >180 days would not be the ideal time to carry out a post-vaccination monitoring 
survey, we would caution against extrapolating this information to estimating protection against 
challenge. Further studies to understand the protective immune response (humoral and cell-
mediated) to SPPV are required.  
 
Conclusions 
Our results show that the use of a commercial CPPV ELISA kit provides a robust and reliable assay for 
post-vaccination surveillance on a regional or national level for SP in low resource settings. Our work 
builds on previous studies investigating the humoral immune response to CPPV vaccination and 
addresses particularly the limited number of studies assessing SP vaccination under field conditions. 
Our results have indicated that the timing of a post-vaccination SP testing survey is an important 
factor to consider when planning post vaccination monitoring.  
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Table 1 Number of positive and negative results using ELISA in two labs (Mongolia and UK) (n=400) 




P value* Kappa test 
 ELISA Mongolia   
ELISA UK 
Num. negatives samples 













*McNemar’s chi squared test for paired data 
 














40 41.93 Positive 83 Positive 80 Positive 
40 0 Negative 2.09 Negative 0 Negative 
40 3.01 Negative 0 Negative 0 Negative 
40 5.32 Negative 2.58 Negative 0 Negative 
74 45.7 Positive 0.48 Negative 0 Negative 
75 17.2 Negative 0 Negative 0 Negative 
76 1.61 Negative 0 Negative 0 Negative 
76 9.07 Negative 1.25 Negative 0 Negative 
76 29.23 Negative 0 Negative 0 Negative 
77 232.86 Positive 210.9 Positive 480 Positive 
77 160.18 Positive 32.81 Positive 120 Positive 
80 7.81 Negative 0.55 Negative 0 Negative 
80 117.84 Positive 325.5 Positive 320 Positive 
80 156.96 Positive 49.47 Positive 80 Positive 
81 83.47 Positive 82.25 Positive 120 Positive 
92 26.77 Negative 1.42 Negative 0 Negative 
92 72.25 Positive 143.3 Positive 30 Positive 
 
 




92 62.25 Positive 0.32 Negative 0 Negative 
102 1.91 Negative 3.7 Negative 0 Negative 
107 46.07 Positive 0 Negative 0 Negative 
110 105.24 Positive 54.56 Positive 30 Positive 
114 3.63 Negative 0.26 Negative 0 Negative 
114 24.4 Negative 0 Negative 0 Negative 
119 33.47 Positive 0 Negative 10 Positive 
121 14.76 Negative 22.32 Negative 20 Positive 
122 0.11 Negative 139.5 Positive 60 Positive 
122 34.83 Positive 181.6 Positive 160 Positive 
122 173.3 Positive 400.1 Positive 1280 Positive 
130 88.57 Positive 130.7 Positive 60 Positive 
131 0 Negative 3.76 Negative 0 Negative 
131 0 Negative 0 Negative 0 Negative 
131 158.88 Positive 252.2 Positive 30 Positive 
132 0 Negative 6.6 Negative 0 Negative 
133 50.27 Positive 101.2 Positive 160 Positive 
135 40.82 Positive 46.3 Positive 0 Negative 
135 0 Negative 0 Negative 0 Negative 
193 43.25 Positive 3.49 Negative 20 Positive 
229 132.41 Positive 169.2 Positive 80 Positive 
229 132.19 Positive 185.3 Positive 60 Positive 
229 0 Negative 2.07 Negative 0 Negative 
229 0 Negative 0.03 Negative 0 Negative 
234 0 Negative 0.19 Negative 0 Negative 
234 0 Negative 1.53 Negative 0 Negative 
236 121.73 Positive 255 Positive 640 Positive 
243 0 Negative 0.3 Negative 0 Negative 
 
Table 3 Number of positive and negative results using FVNT and ELISA in two labs (Mongolia and UK) 
(n=45) 




P value* Kappa test 
 ELISA Mongolia   
FVNT 
Num. negatives samples  













 ELISA lab UK   
 
 





Num. negatives samples  













*McNemar’s chi squared test for paired data 
 
Table 4 Distribution of factors considered for sheep pox serological status after vaccination following 
univariable analysis.  All models include herder as random effect  
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Figure 1 Geographical location of Mongolia (dark brown – top left map) and provinces where 
vaccination was conducted (in alphabetical order) (1)Dornold, (2)Dornogovi, (3)Dungovi, 













Figure 2 Frequency distributions of values among samples, belonging to the 45-sample subset, that 
were deemed positive by each test a); and values among those samples with contradictory results 
between the two labs considering all samples tested (b). Red vertical lines show cut off value used 











Figure 3 Median %SP value using results from SCVL (black line), 1st and 3rd quartile (grey dashed 
lines) and days post vaccination. Red horizontal line represent %S/P cut-off used to classify 
samples as positive/negative. Blue vertical dashed lines are cut-off used to classified days post 
vaccination in categories (<90 days, 91 to 180 days and >180 days) based on the expected 













Table S1 Median and interquartile range for %S/P values stratified by days since vaccination 






Median 3rd quartile 1st quartile Median 
3rd 
quartile 
Up to 90 days 9.08 34.62 117.84 -0.05 2.10 73.14 
Between 91 and 180 
days 
1.6 28.83 64.31 1.58 24.77 79.77 
More than 180 days -6.37 2.89 23.69 -0.15 0.29 1.80 
 
 






















25 40 0.7 (-0.2 – 11.1) 25 40 0.70 (-0.20 – 11.13) 
9 74 45.7 (23.3 – 143.0)  
42 70-79 29.7 (17.5 – 90.9) 
11 75 20.3 (14.3 – 33.1) 
13 76 28.1 (17.4 – 77.8) 
5 77 178.2 (160.2 – 191.4) 
4 79 22.5 (8.3 – 45.5) 
24 80 120.4 (57.9 – 181.3) 
28 80-89 117.8 (63.7 – 179.4) 
4 81 100.7 (77.0 – 136.6) 
 
 




15 92 41.5 (9.9 – 65.7) 
33 90-99 36.8 (17.9 – 58.7) 
18 98 34.0 (24.3 – 48.7) 
19 102 59.8 (38.8 – 100.2) 
36 100-109 60.9 (39.4 – 109.0) 
10 105 65.3 (45.4 – 113.3) 
3 107 83.3 (64.7 – 95.1) 
4 109 5.9 (4.8 – 44.4) 
9 110 114.7 (46.1 – 144.5) 
79 110-119 28.1 (2.9 – 85.1) 
5 112 60.3 (34.8 – 83.9) 
4 113 8.2 (6.3 – 10.9) 
11 114 28.1 (23.3 – 72.0) 
13 116 41.4 (1.8 – 120.0) 
10 118 44.1 (-1.7 – 94.0) 
27 119 11.3 (-4.0 – 34.2) 
6 120 55.3 (1.9 – 128.5) 
23 120-129 14.8 (1.1 – 84.4) 5 121 14.8 (0.3 – 34.6) 
12 122 24.8 (1.6 – 59.6) 
11 130 -4.1 (-6.9 – 10.0) 
74 130-139 4.4 (-0.2 – 35.1) 
24 131 17.6 (0.6 – 34.4) 
6 132 -2.9 (-7.7 – 4.2) 
6 133 10.2 (2.3 – 33.3) 
27 135 0.8 (-0.25 – 41.4) 
12 193 27.2 (10.0 – 50.7)  
55 
≥140 2.9 (-6.4 – 23.7) 
16 229 3.7 (-5.3 – 8.3) 
 
 




4 234 -1.7 (-6.7 – 2.6)  
13 236 1.9 (-6.9 – 34.7) 




Table S3 Time between vaccination and sampling stratified by Province 
Province Time between vaccination 
and sampling (days) 
Median (min- max) 
Dornod (n=79) 80 (74 – 193) 
Dornogovi (n=61) 229 (130 – 243) 
Dundgovi (n=54) 121 (40 – 131) 
Govisumber (n=27) 135 (135 – 135) 
Khentii (n=87) 119 (98 – 131) 
Sukbaatar (n=73) 105 (76 – 114) 
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